復星醫藥(600196.SH):復星實業擬認購1900萬美元MGBⅢ基金份額
格隆匯2月1日丨復星醫藥(600196.SH)公佈,公司控股子公司復星實業(香港)有限公司(以下簡稱“復星實業”)擬作為有限合夥人出資1900萬美元認購Mass General Brigham Fund Ⅲ, L.P.(以下簡稱“MGBⅢ”或“目標基金”)的等值份額。認繳份額約佔目標基金首輪募集總額的10.2%(目標基金計劃募集總額為2.5億美元,其中首輪計劃募集總額為1.87億美元;復星實業實際持有目標基金的份額比例以該基金最終募集完成情況為準)
目標基金將主要專注於在全球範圍內投資高成長性的大健康領域的種子公司及早期公司。本次投資將有利於藉助專業機構的投資能力、渠道及資源,挖掘並儲備行業內的優質項目,促進集團(即公司及控股子公司/單位,下同)在大健康產業相關領域的佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.